Bridging phase 2 and phase 3 pneumococcal immunologic data for future combination vaccines

Clinical Infectious Diseases

Volumn 33, Issue SUPPL. 4, 2001, Pages

  Kayhty H ^a   Ahman H ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE;

CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG USE; GENETIC ANALYSIS; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFANT; LICENSING; MAJOR CLINICAL STUDY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SEROLOGY; STREPTOCOCCUS INFECTION;

ANTIBODIES, BACTERIAL; CHILD; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC MEMORY; INFANT; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; POLYSACCHARIDES, BACTERIAL; VACCINES, CONJUGATE;

EID: 0035893217     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/322565     Document Type: Conference Paper

References (57)

1. Infant pneumococcal vaccine
2. Vaccines against Haemophilus influenzae type b
3. A randomized, placebo-controlled study to evaluate the immunogenicity of an 11-valent pneumococcal protein D conjugate vaccine administered as primary vaccination to infants at 6, 10, and 14 weeks of age
4. Pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine is immunogenic in infants
5. Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well tolerated and able to induce an antibody response in infants
6. Streptococcus pneumoniae capsular polysaccharide - Diphtheria toxoid conjugate vaccine is immunogenic in early infancy and able to induce immunologic memory
7. Dose dependency of antibody response in infants and children to pneumococcal polysaccharides conjugated to tetanus toxoid
8. Serum and salivary anti-capsular antibodies in infants and children immunized with heptavalent pneumococcal conjugate vaccine
9. Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers
10. Safety and immunogenicity of tetravalent pneumococcal vaccines containing 6B, 14, 19F and 23F polysaccharides conjugated to either tetanus toxoid or diphtheria toxoid in young infants and their boosterability by native polysaccharide antigens
11. 197 in United States infants
12. Immune response in an 11-valent pneumococcal polysaccharide-conjugate vaccine in healthy Israeli, Finnish and Icelandic infants
13. Pilot trial of a pentavalent pneumococcal polysaccharide/protein conjugate vaccine in Gambian infants
14. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine
15. Immunogenicity and reactogenicity of a pneumococcal conjugate vaccine administered combined with a Haemophilia influenzae type B conjugate vaccine in United Kingdom infants
16. 197 vaccines: Effect of saccharide size on immunogenicity and interactions with simultaneously administered vaccines
17. Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants
18. A glycoprotein pneumococcal conjugate vaccine primes for antibody responses to a pneumococcal polysaccharide vaccine in Gambian children
19. Immunologic priming of young children by pneumococcal glycoprotein conjugate, but not polysaccharide vaccines
20. Immunogenicity of PncCRM vaccine used in FinOm vaccine trial
21. The effect of a booster dose following primary immunization of an eleven-valent pneumococcal conjugate vaccine in Philippine infants
22. Isotypes and opsonophagocytosis of pneumococcus type 6B antibodies elicited in infants and adults by an experimental pneumococcus type 6B-tetanus toxoid vaccine
23. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children
24. Efficacy of heptavalent conjugate pneumococcal vaccine (Wyeth Lederle) in 37,000 infants and children: Impact on pneumonia, otitis media, and an update on invasive disease-results of extended follow-up of the efficacy trial cohort
25. Efficacy of a pneumococcal conjugate against acute otitis media
26. Effect of a heptavalent pneumococcla conjugate vaccine (PncCRM) on pneumococcal acute otitis media (AOM) by serotype
27. Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine
28. Reduction of pneumococcal nasopharyngeal carriage in early infancy after immunization with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diphtheria toxoid
29. Effect of vaccination with octavalent protein conjugated pneumococcal vaccines on pneumococcal carriage in infants
30. Carriage of pneumococci after pneumococcal vaccination
31. Conjugate vaccines and the carriage of Haemophilus influenzae type b
32. Haemophilus influenzae type b conjugate and combination vaccines
33. Reemergence of invasive Haemophilus influenzae type b disease in a well-vaccinated population in remote Alaska
34. Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines
35. Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization
36. Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines
37. Differences in the avidity of antibodies evoked by four different pneumococcal conjugate vaccines in early childhood
38. Contribution of serotype specific IgG concentration, IgG subclasses, and relative antibody avidity to opsonophagocytic activity against Streptococcus pneumoniae
39. IgG subclass distribution of antibodies after vaccination of adults with pneumococcal conjugate vaccines
40. Tolerability and immunogenicity of an eleven-valent pneumococcal conjugate vaccine in adults
41. A flow cytometric opsonophagocytic assay for measurement of functional antibodies elicited after vaccination with the 23-valent pneumococcal polysaccharide vaccine
42. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus penumoniae using differentiated HL-60 cells
43. Use of highly encapsulated Streptococcus pneumoniae strains in a flow-cytometric assay for assessment of the phagocytic capacity of serotype-specific antibodies
44. Opsonization and antibodies to capsular and cell wall polysaccharides of Streptococcus pneumoniae
45. Are the opsonophagocytic activities of antibodies in infant sera measured by different pneumococcal phagocytosis assays comparable?
46. Characterisation of pneumococcal specific antibodies in healthy unvaccinated adults
47. Identification of cross-reactive antibodies with low opsonophagocytic activity for Streptococcus pneumoniae
48. Are the enzyme immunoassays for antibodies to pneumococcal capsular polysaccharides serotype specific?
49. The pathogenesis of pneumococcal otitis media in chinchillas and the efficacy of vaccination in prophylaxis
50. Correlation of opsonophagocytosis and passive protection assays using human anticapsular antibodies in infant mouse model of bacteremia for Streptococcus pneumoniae
51. A new rat model of otitis media caused by Streptococcus pneumoniae: Conditions and application in immunization protocols
52. Anticapsular polysaccharide antibodies and nasopharyngeal colonization with Streptococcus pneumoniae in infant rats
53. Host cellular immune response to pneumococcal lung infection in mice
54. Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants
55. Salivary anti-capsular antibodies in infants and children immunized with Streptococcus pneumoniae capsular polysaccharide - Tetanus or diphtheria toxoid conjugate vaccines
56. Primary and booster salivary antibody response to a 7-valent conjugate vaccine in infants
57. Salivary antibodies in Finnish children after immunisation with a pneumococcal conjugate vaccine (PncCRM)